Dirk Grimm - Infectious Diseases

Author Information

Dirk Grimm is a prominent researcher affiliated with the Cluster of Excellence CellNetworks at the Department of Infectious Diseases, Virology, Heidelberg University Hospital in Heidelberg, Germany. His work predominantly focuses on the use of viral vectors for gene delivery and therapy, with a particular emphasis on adeno-associated viruses (AAVs) and their applications in treating various diseases.

Research Contributions

Dirk Grimm has made significant contributions to the field of gene therapy and virology. His research includes the development and enhancement of synthetic adeno-associated viral vectors for targeted gene delivery, which holds promise for treating neurological and hearing disorders. He has also contributed to the understanding of immune barriers in vivo, the role of natural killer cells in reprogramming, and the use of RNA interference (RNAi) for suppressing viral infections like SARS-CoV-2. His work extends to exploring novel ways to enhance the specificity and safety of these gene therapy methods.

Aliases

Dirk Grimm is also known by the aliases D Grimm and D. Grimm.

Publication and Citation Metrics

Metric	Value
Total Papers	198
Total Citations	17,086
h-index	50

Publications:

Molecular Signature of Astrocytes for Gene Delivery by the Synthetic Adeno-Associated Viral Vector rAAV9P1.

DOI: 10.1002/advs.202104979

Year: 2022

Induction of Hepatitis E Virus Anti-ORF3 Antibodies from Systemic Administration of a Muscle-Specific Adeno-Associated Virus (AAV) Vector

DOI: 10.3390/v14020266

Year: 2022

Natural killer cells act as an extrinsic barrier for in vivo reprogramming.

DOI: 10.1242/dev.200361

Year: 2022

Breaking the sound barrier: Towards next-generation AAV vectors for gene therapy of hearing disorders

DOI: 10.1016/j.heares.2020.108092

Year: 2022

Direct fluorescent labeling of NF186 and NaV1.6 in living primary neurons using bioorthogonal click chemistry

DOI: 10.1101/2022.03.01.480798

Year: 2022

Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors

DOI: 10.1016/j.ymthe.2022.01.024

Year: 2022

Right on target: The next class of efficient, safe, and specific RNAi triggers

DOI: 10.1016/j.omtn.2022.03.027

Year: 2022

Methane formation driven by reactive oxygen species across all living organisms.

DOI: 10.1038/s41586-022-04511-9

Year: 2022

In vivo high-throughput screening of novel adeno-associated viral capsids targeting adult neural stem cells in the subventricular zone

DOI: 10.1101/2021.03.05.434064

Year: 2021

Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8

DOI: 10.1016/j.omtm.2021.09.014

Year: 2021

What is Fatty Acid Biosynthesis?

How Often Should You Get a Health Check-Up?

What Pathogens Can Be Detected in Stool Samples?

How is Dengue Transmitted?

What is West Nile Virus?

When Are Antivirals Prescribed?

What is Parasite DNA?

What is Artemisinin?

How Do Fungal Pathogens Affect Us?

What is Polymerase Chain Reaction (PCR)?

Partnered Content Networks

Relevant Topics